Vivos Therapeutics and Empower Sleep Launch Cooperative Relationship Aimed at Significantly Improving Proper Obstructive Sleep Apnea Diagnosis and Treatment

HIGHLANDS RANCH, Colo., Aug. 26, 2021 (GLOBE NEWSWIRE) -- . (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA), today announced a new cooperative relationship with Empower Sleep, a San Bernardino, Calif.-based company empowering patients with affordable, accessible and personalized telemedicine sleep care, to provide critical diagnostic and medical consultation services to people across North America who suffer from OSA.

Together, Vivos and Empower Sleep plan to leverage each company’s core technologies to provide a user-friendly platform with personalized insights for patients who are being screened for OSA by North American dentists and other healthcare providers. This relationship is expected to enable more patients than ever before to better discover how well they are breathing and sleeping every night, as well as understand the effects that sleep can have on overall health. As a result, patients will be able to receive the appropriate treatment for any sleep-disordered breathing disorder, including mild to moderate OSA.

Central to this collaboration is the Company’s VivoScore product, powered by SleepImage, a biometric ring recording device that allows patients to readily take a simple, comfortable sleep test in the privacy of their own homes. The test results will be automatically uploaded and interpreted by independent physicians and qualified personnel at Empower Sleep. From there, treatment or a telemedicine consultation may be recommended, or a consult with a medical doctor and dentist may be scheduled for a collaborative treatment approach for those who tested positive for OSA.

As part of a recent, unrelated pilot study consisting of nearly 1,000 patients and performed by 12 independent Vivos-trained dentists, VivoScore identified a positive OSA diagnosis in over half (56 percent) of patients studied. Additionally, after receiving a confirming diagnosis from a physician, 50 percent of all patients who tested positive entered into treatment for OSA with the Company’s core product, the Vivos System.

“Our trained providers’ VivoScore sleep test use has increased by more than 300 percent from just a few weeks ago,” said Kirk Huntsman, Vivos Chairman and CEO. “What’s more, about half of those patients are testing positive for OSA. Simply put, VivoScore is gaining traction, and we believe that this new cooperative relationship with Empower Sleep will add a vital medical diagnostic and consultative component to our patient-friendly sleep apnea treatment ecosystem. We believe that more screenings and confirmed diagnoses of OSA mean that more patients will seek what is often lifesaving treatment for their OSA, which may include using the Vivos System.”

“We are thrilled to be collaborating with Vivos,” added Dr. Sahil Chopra, MD, sleep specialist and Empower Sleep Founder and CEO. “Our mission is to empower patients through giving them access to personalized online sleep care. By working with Vivos and being able to prescribe the Vivos System as a treatment option, we are able to make sleep care even more personalized and patient-specific. With over 40 percent of patients intolerant to CPAP devices, the Vivos System is a promising alternative.”

About Vivos Therapeutics, Inc.

Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from mild-to-moderate obstructive sleep apnea (OSA). The Vivos treatment involves customized oral appliances and treatment protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for adults with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients treated worldwide by more than 1,250 trained dentists.

Combining proprietary technologies and protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology, for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.

For more information, visit .

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “aim”, “may”, “could”, “expects”, “projects,” “intends”, “plans”, “believes”, “predicts”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the anticipated benefits of the Company’s collaboration with Empower Sleep as described herein) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC's website at Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

Investor Relations Contact:

Edward Loew

Investor Relations Officer

(602) 903-0095

Media Relations Contact:

Caitlin Kasunich / Jenny Robles

KCSA Strategic Communications

(212) 896-1241 / (212) 896-1231

/